Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

Albert Lockhart, Todd M. Bauer, Charu Aggarwal, Carrie B. Lee, R. Donald Harvey, Roger B. Cohen, Farhad Sedarati, Tsz Keung Nip, Hélène Faessel, Ajeeta B. Dash, Bruce J. Dezube, Douglas V. Faller, Afshin Dowlati

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Summary: Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received pevonedistat with docetaxel (arm 1, n = 22), carboplatin plus paclitaxel (arm 2, n = 26), or gemcitabine (arm 3, n = 10) in 21-days (arms 1 and 2) or 28-days (arm 3) cycles. A lead-in cohort (arm 2a, n = 6) determined the arm 2 carboplatin dose. Dose escalation proceeded via continual modified reassessment. Results Pevonedistat MTD was 25 mg/m2 (arm 1) or 20 mg/m2 (arm 2); arm 3 was discontinued due to poor tolerability. Fifteen (23%) patients experienced dose-limiting toxicities during cycle 1 (grade ≥3 liver enzyme elevations, febrile neutropenia, and thrombocytopenia), managed with dose holds or reductions. Drug-related adverse events (AEs) occurred in 95% of patients. Most common AEs included fatigue (56%) and nausea (50%). One drug-related death occurred in arm 3 (febrile neutropenia). Pevonedistat exposure increased when co-administered with carboplatin plus paclitaxel; no obvious changes were observed when co-administered with docetaxel or gemcitabine. Among 54 response-evaluable patients, two had complete responses (arm 2) and 10 had partial responses (three in arm 1, one in arm 2a, six in arm 2); overall response rates were 16% (arm 1) and 35% (arm 2). High ERCC1 expression correlated with clinical benefit in arm 2. Conclusion Pevonedistat with docetaxel or with carboplatin plus paclitaxel was tolerable without cumulative toxicity. Sustained clinical responses were observed in pretreated patients receiving pevonedistat with carboplatin and paclitaxel. ClinicalTrials.govidentifier: NCT01862328.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalInvestigational New Drugs
DOIs
StateAccepted/In press - May 21 2018

Fingerprint

docetaxel
gemcitabine
Carboplatin
Enzyme Inhibitors
Paclitaxel
Febrile Neutropenia
Neoplasms
Maximum Tolerated Dose
Standard of Care
Drug-Related Side Effects and Adverse Reactions
Thrombocytopenia
Nausea
Fatigue
Safety

Keywords

  • Advanced solid tumors
  • Clinical research
  • Pevonedistat
  • Phase Ib study
  • Standard-of-care chemotherapies

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. / Lockhart, Albert; Bauer, Todd M.; Aggarwal, Charu; Lee, Carrie B.; Harvey, R. Donald; Cohen, Roger B.; Sedarati, Farhad; Nip, Tsz Keung; Faessel, Hélène; Dash, Ajeeta B.; Dezube, Bruce J.; Faller, Douglas V.; Dowlati, Afshin.

In: Investigational New Drugs, 21.05.2018, p. 1-11.

Research output: Contribution to journalArticle

Lockhart, Albert ; Bauer, Todd M. ; Aggarwal, Charu ; Lee, Carrie B. ; Harvey, R. Donald ; Cohen, Roger B. ; Sedarati, Farhad ; Nip, Tsz Keung ; Faessel, Hélène ; Dash, Ajeeta B. ; Dezube, Bruce J. ; Faller, Douglas V. ; Dowlati, Afshin. / Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. In: Investigational New Drugs. 2018 ; pp. 1-11.
@article{6e931b99eb364f4ebc0790190c2fb8cb,
title = "Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors",
abstract = "Summary: Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received pevonedistat with docetaxel (arm 1, n = 22), carboplatin plus paclitaxel (arm 2, n = 26), or gemcitabine (arm 3, n = 10) in 21-days (arms 1 and 2) or 28-days (arm 3) cycles. A lead-in cohort (arm 2a, n = 6) determined the arm 2 carboplatin dose. Dose escalation proceeded via continual modified reassessment. Results Pevonedistat MTD was 25 mg/m2 (arm 1) or 20 mg/m2 (arm 2); arm 3 was discontinued due to poor tolerability. Fifteen (23{\%}) patients experienced dose-limiting toxicities during cycle 1 (grade ≥3 liver enzyme elevations, febrile neutropenia, and thrombocytopenia), managed with dose holds or reductions. Drug-related adverse events (AEs) occurred in 95{\%} of patients. Most common AEs included fatigue (56{\%}) and nausea (50{\%}). One drug-related death occurred in arm 3 (febrile neutropenia). Pevonedistat exposure increased when co-administered with carboplatin plus paclitaxel; no obvious changes were observed when co-administered with docetaxel or gemcitabine. Among 54 response-evaluable patients, two had complete responses (arm 2) and 10 had partial responses (three in arm 1, one in arm 2a, six in arm 2); overall response rates were 16{\%} (arm 1) and 35{\%} (arm 2). High ERCC1 expression correlated with clinical benefit in arm 2. Conclusion Pevonedistat with docetaxel or with carboplatin plus paclitaxel was tolerable without cumulative toxicity. Sustained clinical responses were observed in pretreated patients receiving pevonedistat with carboplatin and paclitaxel. ClinicalTrials.govidentifier: NCT01862328.",
keywords = "Advanced solid tumors, Clinical research, Pevonedistat, Phase Ib study, Standard-of-care chemotherapies",
author = "Albert Lockhart and Bauer, {Todd M.} and Charu Aggarwal and Lee, {Carrie B.} and Harvey, {R. Donald} and Cohen, {Roger B.} and Farhad Sedarati and Nip, {Tsz Keung} and H{\'e}l{\`e}ne Faessel and Dash, {Ajeeta B.} and Dezube, {Bruce J.} and Faller, {Douglas V.} and Afshin Dowlati",
year = "2018",
month = "5",
day = "21",
doi = "10.1007/s10637-018-0610-0",
language = "English (US)",
pages = "1--11",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

AU - Lockhart, Albert

AU - Bauer, Todd M.

AU - Aggarwal, Charu

AU - Lee, Carrie B.

AU - Harvey, R. Donald

AU - Cohen, Roger B.

AU - Sedarati, Farhad

AU - Nip, Tsz Keung

AU - Faessel, Hélène

AU - Dash, Ajeeta B.

AU - Dezube, Bruce J.

AU - Faller, Douglas V.

AU - Dowlati, Afshin

PY - 2018/5/21

Y1 - 2018/5/21

N2 - Summary: Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received pevonedistat with docetaxel (arm 1, n = 22), carboplatin plus paclitaxel (arm 2, n = 26), or gemcitabine (arm 3, n = 10) in 21-days (arms 1 and 2) or 28-days (arm 3) cycles. A lead-in cohort (arm 2a, n = 6) determined the arm 2 carboplatin dose. Dose escalation proceeded via continual modified reassessment. Results Pevonedistat MTD was 25 mg/m2 (arm 1) or 20 mg/m2 (arm 2); arm 3 was discontinued due to poor tolerability. Fifteen (23%) patients experienced dose-limiting toxicities during cycle 1 (grade ≥3 liver enzyme elevations, febrile neutropenia, and thrombocytopenia), managed with dose holds or reductions. Drug-related adverse events (AEs) occurred in 95% of patients. Most common AEs included fatigue (56%) and nausea (50%). One drug-related death occurred in arm 3 (febrile neutropenia). Pevonedistat exposure increased when co-administered with carboplatin plus paclitaxel; no obvious changes were observed when co-administered with docetaxel or gemcitabine. Among 54 response-evaluable patients, two had complete responses (arm 2) and 10 had partial responses (three in arm 1, one in arm 2a, six in arm 2); overall response rates were 16% (arm 1) and 35% (arm 2). High ERCC1 expression correlated with clinical benefit in arm 2. Conclusion Pevonedistat with docetaxel or with carboplatin plus paclitaxel was tolerable without cumulative toxicity. Sustained clinical responses were observed in pretreated patients receiving pevonedistat with carboplatin and paclitaxel. ClinicalTrials.govidentifier: NCT01862328.

AB - Summary: Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received pevonedistat with docetaxel (arm 1, n = 22), carboplatin plus paclitaxel (arm 2, n = 26), or gemcitabine (arm 3, n = 10) in 21-days (arms 1 and 2) or 28-days (arm 3) cycles. A lead-in cohort (arm 2a, n = 6) determined the arm 2 carboplatin dose. Dose escalation proceeded via continual modified reassessment. Results Pevonedistat MTD was 25 mg/m2 (arm 1) or 20 mg/m2 (arm 2); arm 3 was discontinued due to poor tolerability. Fifteen (23%) patients experienced dose-limiting toxicities during cycle 1 (grade ≥3 liver enzyme elevations, febrile neutropenia, and thrombocytopenia), managed with dose holds or reductions. Drug-related adverse events (AEs) occurred in 95% of patients. Most common AEs included fatigue (56%) and nausea (50%). One drug-related death occurred in arm 3 (febrile neutropenia). Pevonedistat exposure increased when co-administered with carboplatin plus paclitaxel; no obvious changes were observed when co-administered with docetaxel or gemcitabine. Among 54 response-evaluable patients, two had complete responses (arm 2) and 10 had partial responses (three in arm 1, one in arm 2a, six in arm 2); overall response rates were 16% (arm 1) and 35% (arm 2). High ERCC1 expression correlated with clinical benefit in arm 2. Conclusion Pevonedistat with docetaxel or with carboplatin plus paclitaxel was tolerable without cumulative toxicity. Sustained clinical responses were observed in pretreated patients receiving pevonedistat with carboplatin and paclitaxel. ClinicalTrials.govidentifier: NCT01862328.

KW - Advanced solid tumors

KW - Clinical research

KW - Pevonedistat

KW - Phase Ib study

KW - Standard-of-care chemotherapies

UR - http://www.scopus.com/inward/record.url?scp=85047166737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047166737&partnerID=8YFLogxK

U2 - 10.1007/s10637-018-0610-0

DO - 10.1007/s10637-018-0610-0

M3 - Article

C2 - 29781056

AN - SCOPUS:85047166737

SP - 1

EP - 11

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

ER -